Hanks et al. [28] concluded that elevated FGF23 concentrations could serve as a subclinical marker of metabolic perturbations (diabetes, dyslipidemia, and obesity) in individuals with normal kidney function. The gene discussed is FGF23; the disease is obesity disorder.